A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

NCT04417517 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
65
Enrollment
INDUSTRY
Sponsor class

Stopped While intended to be a Phase 1/2 clinical study, the study did not proceed to Phase 2.

Conditions

Interventions

Sponsor

ALX Oncology Inc.